Exploiting the early immune response in Chikungunya fever promises to provide protection.
Chikungunya fever is a viral disease that has re-emerged to cause epidemics in the Pacific region within the last decade. It is caused by the Chikungunya virus (CHIKV), which is transmitted by mosquitoes and causes symptoms including fever, rash and joint pain. It can be incapacitating, with some patients developing severe chronic symptoms, and it is sometimes fatal. The main current control measure is to prevent exposure to mosquitoes; a vaccine would reduce the threat of CHIKV.
Lisa Ng of the A*STAR Singapore Immunology Network and co-workers have now provided insight into the natural immune response that may help in developing a vaccine. Ng's group showed previously that the initial immune response to CHIKV is spearheaded by a specific class of antibody that disables the virus when bound to it. Their latest research reveals a way to exploit this clinically.
Working with clinicians at the Tan Tock Seng Hospital, Ng and her team took blood samples from CHIKV-infected patients and tested them to see if they contained any antibodies that recognize proteins from the surface of the virus. They found that at early stages of recovery, patients' blood contained large amounts of an antibody that targets a protein known as E2, which projects from the surface of CHIKV (see image). The same antibody was found in different groups of patients, showing that it is a reliable indicator of early infection.
The team confirmed that this antibody neutralizes CHIKV by adding blood samples to virus which was then used to infect susceptible human cells. If the blood samples contained the antibody, infection rates were reduced, whereas removing the antibody from the samples beforehand left infection rates high.
Having identified that the antibody recognizes E2, the researchers then tested its ability to recognize fragments of the protein. This allowed identification of the epitope, or the exact site on the protein, that the antibody binds to, which they called E2EP3.
When they vaccinated mice with a protein fragment equivalent to this epitope, the mice produced the same antibody in response. On subsequent infection with CHIKV, the vaccinated mice also showed milder symptoms, making the epitope a promising basis for a future vaccine in humans.
"[This study is] highly relevant for the rational design of CHIKV vaccines and for the development of diagnostics for optimal clinical management of patients," says Ng. "It may also inspire similar studies with other arthritic arboviruses that in many parts of the world cause severe morbidity with extensive incapacitation."
The above story is based on materials provided by The Agency for Science, Technology and Research (A*STAR). Note: Materials may be edited for content and length.
- Yiu-Wing Kam, Fok-Moon Lum, Teck-Hui Teo, Wendy W. L. Lee, Diane Simarmata, Sumitro Harjanto, Chong-Long Chua, Yoke-Fun Chan, Jin-Kiat Wee, Angela Chow, Raymond T. P. Lin, Yee-Sin Leo, Roger Le Grand, I-Ching Sam, Joo-Chuan Tong, Pierre Roques, Karl-Heinz Wiesmüller, Laurent Rénia, Olaf Rötzschke, Lisa F. P. Ng. Early neutralizing IgG response to Chikungunya virus in infected patients targets a dominant linear epitope on the E2 glycoprotein. EMBO Molecular Medicine, 2012; 4 (4): 330 DOI: 10.1002/emmm.201200213
Cite This Page: